• search

Roche launches 'Tarceva' for lung cancer patients

Written by: Staff

Mumbai, Apr 11 (UNI) Roche Scientific Company today launched a drug 'Tarceva' to treat small cell lung cancer in India.

Company Managing Director Dr G L Telang said, ''Tarceva is the only epidermal growth factor receptor to have demonstrated a survival benefit in lung cancer.'' Non small cell lung cancer accounts for almost 80 per cent of all lung cancer cases and there are few treatment options available.

He said that not only Tarceva demonstrates a striking survival benefit in advaced on-small cell lung cancer by six to nine months but also has shown a significantly improvement in the quality of patients' life by allevating severe and delibitating symptoms that are characteristics of advanced disease.

Dr Telang said that curretly most people with lung cancer are treated with chemotherapy, which can be very debilitating due to its toxic nature but Tarceva works differently by specifically targeting tumour cells, thus avoiding the typical side-effects of chemotherapy.

He further said, a ten tablet strips costs Rs 32,000 plus the prevailing taxes that will cost a patient over Rs three lakhs for a three-month course.

He said that presently patient's have to bear high financial costs-both in terms of direct and indirect costs like hospital care, lost working days etc. But this can be saved by using the new drug, he emphasised.

He said the company had approached the ministry to get tax exemption on Tarceva drugs enabling it to cut down the prevailing costs by about 35 per cent. He added, ''The ministry has promised to look into the matter.'' UNI PVN KU RL ND1626

For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more